MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412547 | Name: Cefuzonam (free base)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefuzonam (free base) is a second-generation cephalosporin antibiotic.

Chemical Structure

Cefuzonam (free base)
CAS#82219-78-1 (free base)

Theoretical Analysis

MedKoo Cat#: 412547

Name: Cefuzonam (free base)

CAS#: 82219-78-1 (free base)

Chemical Formula: C16H15N7O5S4

Exact Mass: 513.0017

Molecular Weight: 513.58

Elemental Analysis: C, 37.42; H, 2.94; N, 19.09; O, 15.58; S, 24.97

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
82219-78-1 (free base) 82219-81-6 (Na+)
Synonym
Cefuzonam (free base); Cefuzonamum; UNII-860MT00T7T
IUPAC/Chemical Name
(6R,7R)-3-(((1,2,3-thiadiazol-5-yl)thio)methyl)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
InChi Key
CXHKZHZLDMQGFF-ZSDSSEDPSA-N
InChi Code
InChI=1S/C16H15N7O5S4/c1-28-21-9(7-5-31-16(17)19-7)12(24)20-10-13(25)23-11(15(26)27)6(4-30-14(10)23)3-29-8-2-18-22-32-8/h2,5,10,14H,3-4H2,1H3,(H2,17,19)(H,20,24)(H,26,27)/b21-9-/t10-,14-/m1/s1
SMILES Code
CO/N=C(c1nc(N)sc1)\C(N[C@H]2[C@H]3SCC(CSc4snnc4)=C(C(O)=O)N3C2=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 513.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Nishimura T, Tabuki K, Takashima T, Takagi M. [Laboratory and clinical studies of cefuzonam in pediatric field]. Jpn J Antibiot. 1987 Feb;40(2):427-38. Japanese. PMID: 3599391. 2: Hara K, Matsumoto F. [New antimicrobial agent series XXVIII: cefuzonam]. Jpn J Antibiot. 1987 Dec;40(12):1953-63. Japanese. PMID: 3329242. 3: Nakazawa S, Sato H, Narita A, Matsumoto K, Suzuki H, Nakazawa S, Chikaoka H, Koido R, Kamigaki M, Nakada Y, et al. [Evaluation of cefuzonam in the pediatric field]. Jpn J Antibiot. 1987 Mar;40(3):613-29. Japanese. PMID: 3613082. 4: Igari J, Oguri T, Higuchi T. Evaluation of minocycline and cefuzonam for antimicrobial activity against clinical isolates. Jpn J Antibiot. 1994 Aug;47(8):1013-29. PMID: 7933531. 5: Deguchi K, Yokota N, Koguchi M, Nakane Y, Suzuki Y, Fukayama S, Ishihara R. [Bacteriological evaluations of combination therapies with minocycline and beta- lactams for methicillin-resistant Staphylococcus aureus. II. cefuzonam plus minocycline]. Jpn J Antibiot. 1992 Jun;45(6):605-11. Japanese. PMID: 1507394. 6: Matsuda S, Suzuki M, Miyazaki R, Shimizu T, Mure K, Soma A, Hasegawa T, Haga H, Saito T, Saito S, et al. [Pharmacokinetic, bacteriological and clinical studies of cefuzonam in the field of obstetrics and gynecology. Study group of cefuzonam in the field of obstetrics and gynecological infections]. Jpn J Antibiot. 1988 Aug;41(8):971-96. Japanese. PMID: 3050195. 7: Masuyoshi S, Hiraoka M, Inoue M, Tomatsu K, Hirano M, Mitsuhashi S. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime. Drugs Exp Clin Res. 1989;15(1):1-10. PMID: 2663406. 8: Kuno K, Hakamada S, Miyachi Y, Nakashima T, Hayakawa F, Miura K, Miyajima Y. [Fundamental and clinical studies on cefuzonam in the field of pediatrics]. Jpn J Antibiot. 1987 Feb;40(2):405-18. Japanese. PMID: 3599389. 9: Matsuda S, Suzuki M. [Clinical studies on cefuzonam in obstetrics and gynecological infections]. Jpn J Antibiot. 1987 May;40(5):1041-6. Japanese. PMID: 3669283. 10: Okumura A, Ito K, Kondo M, Takahashi H, Hayakawa F, Ogawa A, Kuno K. Infective endocarditis caused by highly penicillin-resistant Streptococcus pneumoniae: successful treatment with cefuzonam, ampicillin and imipenem. Pediatr Infect Dis J. 1995 Apr;14(4):327-9. doi: 10.1097/00006454-199504000-00019. PMID: 7603821.